Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Autonomix Medical finalizes ASIC microchip design | 1 | Investing.com | ||
AUTONOMIX MEDICAL Aktie jetzt für 0€ handeln | |||||
Fr | Autonomix Medical, Inc. Finalizes Design of ASIC Microchip for Sensing Technology Catheter for Use in Humans, Continuing Progress Toward a U.S. Pivotal Trial in 2025 | 6 | GlobeNewswire (USA) | ||
15.01. | Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series | 3 | GlobeNewswire (USA) | ||
13.01. | Autonomix Medical, Inc. Announces Abstract Highlighting Preliminary Positive Clinical Results Accepted at The Society of Interventional Oncology (SIO) 2025 Annual Scientific Meeting | 59 | GlobeNewswire (Europe) | THE WOODLANDS, TX, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to... ► Artikel lesen | |
30.12.24 | Autonomix secures U.S. patent for cancer-treating tech | 1 | MassDevice | ||
30.12.24 | What's Going On With Autonomix Medical Stock Monday? | 2 | Benzinga.com | ||
30.12.24 | Autonomix Medical, Inc. Announces U.S. Patent Granted Covering the Treatment of Cancerous Tumors and Cancer Related Pain with Company's Proprietary Catheter-Based Technology | 111 | GlobeNewswire (Europe) | Growing global patent portfolio to over 120 patents with 80 issued patents and over 40 pending patent applications Previously completed preclinical study evaluating targeted nerve ablation demonstrated... ► Artikel lesen | |
23.12.24 | Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment | 1 | GlobeNewswire (USA) | ||
19.12.24 | Autonomix Medical, Inc. Drives Towards U.S. Pivotal Trial with Appointment of Vice President, Regulatory Affairs and Quality | 1 | GlobeNewswire (USA) | ||
05.12.24 | Autonomix Medical, Inc. Achieves Design Lock for RF Ablation Catheter Following Successful Completion of Animal Testing, Continuing Progress Toward a U.S. Pivotal Trial in 2025 | 1 | GlobeNewswire (USA) | ||
25.11.24 | Autonomix Medical, Inc. - 8-K, Current Report | - | SEC Filings | ||
25.11.24 | Autonomix Medical, Inc. Announces Closing of $10.0 Million Underwritten Public Offering Including Partial Exercise of Over-Allotment Option | 1 | GlobeNewswire (USA) | ||
25.11.24 | Autonomix Medical stock dips after pricing $9M securities offering | 1 | Seeking Alpha | ||
22.11.24 | Autonomix Medical, Inc. Announces Pricing of $9.0 Million Underwritten Public Offering | 3 | GlobeNewswire (USA) | ||
11.11.24 | Autonomix Medical reports Q2 results | 2 | Seeking Alpha | ||
11.11.24 | Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update | 102 | GlobeNewswire (Europe) | Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer; Preliminary results demonstrate 100% of the lead-in patient responder group went to zero opioid use at 4-6... ► Artikel lesen | |
08.11.24 | Autonomix Medical, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
04.11.24 | Autonomix Medical, Inc. - 8-K, Current Report | - | SEC Filings | ||
01.11.24 | Autonomix Medical, Inc. - S-1, General form for registration of securities | 2 | SEC Filings | ||
31.10.24 | Pre-market Movers: Root, Inc., Autonomix Medical, Avadel Pharmaceuticals, Estée Lauder, Alphatec Holdings | 662 | AFX News | DUBLIN (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 09.10 A.M. ET).In the Green Root, Inc. (ROOT) is up over 94% at $78.85.
Autonomix... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SIEMENS HEALTHINEERS | 53,78 | +3,22 % | Siemens Healthineers-Aktie: Kurs klettert leicht (53,42 €) | Am deutschen Aktienmarkt liegt das Wertpapier von Siemens Healthineers aktuell im Plus. Die Aktie kostete zuletzt 53,42 Euro. Die Aktie von Siemens Healthineers verzeichnet gegenwärtig einen Wertanstieg... ► Artikel lesen | |
FRESENIUS | 36,210 | -0,47 % | Fresenius SE Aktie: Zeichen stehen auf Gewinn | Die Fresenius SE-Aktie zeigt sich am Handelstag in robuster Verfassung und verzeichnet eine positive Entwicklung im XETRA-Handel. Das Wertpapier konnte im Tagesverlauf um 0,6 Prozent zulegen und erreichte... ► Artikel lesen | |
FRESENIUS MEDICAL CARE | 44,340 | -0,36 % | GOLDMAN SACHS stuft FMC FRESENIUS MEDICAL CARE AG & CO KGAA auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat die Einstufung für FMC mit einem Kursziel von 52 Euro auf "Buy" belassen. Analyst Richard Felton nahm in einer am Montagabend vorliegenden... ► Artikel lesen | |
GERRESHEIMER | 67,05 | +2,52 % | EQS-PVR: Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Gerresheimer AG
Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of... ► Artikel lesen | |
BRIGHTSPRING HEALTH SERVICES | 20,890 | +12,61 % | BrightSpring Health Services, Inc. Enters into Definitive Agreement to Divest Community Living Business to Sevita; Reports Preliminary 2024 Financial Results and Provides 2025 Guidance Excluding Community Living | Streamlined organization and Provider Services segment to optimize resource allocationProvider Services focus on Home Health/Hospice, Personal Care, Rehabilitation Services, and Care Management strategic... ► Artikel lesen | |
CARL ZEISS MEDITEC | 48,800 | +1,41 % | JPMORGAN stuft CARL ZEISS MEDITEC AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Carl Zeiss Meditec mit einem Kursziel von 40 Euro auf "Underweight" belassen. Das erste Geschäftsquartal dürfte mau ausfallen... ► Artikel lesen | |
ATRICURE | 39,630 | +3,02 % | AtriCure (NASDAQ:ATRC) Hits New 52-Week High - Should You Buy? | ||
PROCEPT BIOROBOTICS | 69,72 | 0,00 % | PROCEPT BioRobotics (NASDAQ:PRCT) Trading Down 2.8% - Should You Sell? | ||
GENEDX | 74,33 | 0,00 % | GeneDx Announces Preliminary 2024 Financial Results | STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for... ► Artikel lesen | |
HIMS & HERS HEALTH | 28,680 | +0,31 % | Hims & Hers Health Unusual Options Activity | ||
UNITEDHEALTH | 503,70 | +0,02 % | AKTIE IM FOKUS: UnitedHealth sehr schwach nach Zahlen - Erholungstrend gefährdet | NEW YORK (dpa-AFX) - Mit Kursabschlägen von mehr als 5 Prozent haben die Anleger von UnitedHealth am Donnerstag die Geschäftszahlen des US-Krankenversicherers quittiert. Im nur leicht schwächeren Leitindex... ► Artikel lesen | |
RXSIGHT | 30,920 | 0,00 % | RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance | ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) - RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following... ► Artikel lesen | |
INTUITIVE SURGICAL | 580,00 | +0,07 % | Soll ich diese Aktien jetzt kaufen? Intel, Intuitive Surgical und UnitedHealth im Check | In der neuesten Folge von "Money Train" begrüßen wir Martin Weiß, stellvertretender Chefredakteur bei DER AKTIONÄR. Gemeinsam analysieren wir die aktuelle Lage bei Intel, Intuitive Surgical und UnitedHealth... ► Artikel lesen | |
DRAEGERWERK | 55,90 | +2,01 % | HAUCK AUFHÄUSER INVESTMENT BANKING stuft Draegerwerk auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Hauck Aufhäuser Investment Banking hat die Einstufung für Drägerwerk mit einem Kursziel von 86 Euro auf "Buy" belassen. Bei Drägerwerk-Aktien müsse man ausnahmsweise der... ► Artikel lesen | |
PROGYNY | 21,470 | +2,29 % | Progyny beruft Gesundheitsexpertin Debra Morris in den Vorstand |